FGF-23 in patients with end-stage renal disease on hemodialysis
- 1 May 2004
- journal article
- Published by Elsevier BV in Kidney International
- Vol. 65 (5), 1943-1946
- https://doi.org/10.1111/j.1523-1755.2004.00604.x
Abstract
FGF-23 in patients with end-stage renal disease on hemodialysis. Background Fibroblast growth factor (FGF)-23 is a recently identified circulating factor which causes renal phosphate wasting disorders. Although the mechanism of regulation of FGF-23 secretion is unknown, plasma FGF-23 level may be regulated or affected by serum phosphate levels because of its hypophosphatemic effect. Methods We tested the hypothesis that plasma FGF-23 levels may be increased in hyperphosphatemia in patients with end-stage renal disease (ESRD) on maintenance hemodialysis. We measured plasma FGF-23 levels in 158 male uremic patients on maintenance hemodialysis. Plasma samples were obtained before starting dialysis sessions to determine FGF-23 levels by enzyme-linked immunosorbent assay (ELISA). Results Plasma FGF-23 level exhibited significant and positive correlations with inorganic phosphate, intact parathyroid hormone (PTH), corrected calcium, and duration of hemodialysis on simple regression analyses. All these associations remained significant in multiple regression analyses. Conclusion Serum phosphate, calcium, and intact PTH could be regulators of FGF-23 levels in uremic patients on maintenance hemodialysis. Our results may provide new insights into the pathophysiologic effects of FGF-23 on calcium-phosphate homeostasis.Keywords
This publication has 9 references indexed in Scilit:
- Increased Circulatory Level of Biologically Active Full-Length FGF-23 in Patients with Hypophosphatemic Rickets/OsteomalaciaJournal of Clinical Endocrinology & Metabolism, 2002
- Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23Kidney International, 2001
- Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalaciaProceedings of the National Academy of Sciences of the United States of America, 2001
- The Autosomal Dominant Hypophosphatemic Rickets (ADHR) Gene Is a Secreted Polypeptide Overexpressed by Tumors that Cause Phosphate WastingJournal of Clinical Endocrinology & Metabolism, 2001
- Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23Nature Genetics, 2000
- Control of serum phosphate in patients with renal failure--new approaches.Nephrology Dialysis Transplantation, 1998
- A gene (PEX) with homologies to endopeptidases is mutated in patients with X–linked hypophosphatemic ricketsNature Genetics, 1995
- Tumor-Induced Osteomalacia -- Unveiling a New HormoneNew England Journal of Medicine, 1994
- Serum Parathyroid Hormone in X-Linked HypophosphatemiaScience, 1971